Numico achieved sales of EUR 4.2 billion in 2000, an increase of 84 %. Earnings before interest, taxes and amortisation of goodwill (EBITA) rose by 95 % to EUR 660 million.
Cash Earnings (net profit before goodwill amortisation) increased by 72 % to EUR 375 million (1999: EUR 218).
Cash earnings per share rose by 51% to EUR 2.42 (based on an average number of shares of 155 million).
EBITA margin rose to 15.6% (14.7% in 1999).

The results are fully in line with the forecast published in August 2000.


Infant Nutrition


Sales in this product group rose by 11 % to EUR 923 million. The Infant Nutrition Group performed well, showing a strong increase in the Asia Pacific region and even in mature markets such as Western Europe. The introduction of the innovative infant formula Omneo/Conformil and the follow-on concept “Stage 3” strongly contributed to these results.


Clinical Nutrition


This product group showed an increase in sales of 15% to EUR 427 million. New products were introduced in several markets. Numico is furthermore focussing on the home care market, which is a strong growing market segment.


Nutritional Supplements


Sales in this product group rose to a total of EUR 2.3 billion, an increase of 259%.
GNC‘s comparable store sales rose by 6.5% for the full year.
In this product group a distinction should be made between Numico’s activities as a Retailer (GNC, Inc.) and the manufacturing and sales of proprietary brands to the retail (including GNC) which activities are comparable with those in the other product groups. The retail business is inter alia important for Numico to maintain the possibility to introduce new innovative products directly to the consumer market.



Market Developments


In the table below an overview is given of the various categories of Numico’s sales for 2000 (annualized). In the last column Numico’s view on the general market developments for 2001 is reflected. Numico expects to outperform these developments, especially in the branded products categories.


Annualized sales in million Euro (incl. Rexall and Enrich for the full year)



























































Category

Sales 2000

Relative importance of the category
(in %)

Expected market developments
(sales growth % 2001)
A. Branded Products
 

 

 
Infant Nutrition
923

20

Europe: approx. 3 %
Rest: > 10%
Clinical Nutrition
427

9

Approx. 15 %
Nutritional supplements:
– Diet/Sports
– Vitamins/Herbs
– Europe


580
780
100


13
16
2


Approx. 15 %
Limited
Approx. 15 %
Subtotal
 

60

 
B. Dairy & Drinks + Others
545

11

Approx. 5 %
C. Retail
– GNC and Unicity*


-3rd party supplies to franchisees


1,154


250


24
(of which sports/diet =10
and vitamins/herbs= 10)
5



Approx. 2-4 %


Subtotal
4,759

100

 
Elimination of internal deliveries* *
(279)

 

 
Total Sales
4,480

 

 
* multi-level marketing organisation (former Enrich International Inc. and Rexall Showcase International)
** supply of branded products to GNC retail.

The table shows that Numico’s core activities are for a major part to be found in significantly growing market segments.
Numico will release its final results for 2000 and the outlook for 2001 on March 6, 2001, after closing of the trade in Amsterdam.